VPS51 inhibitors are a class of chemical compounds specifically designed to target and inhibit the VPS51 protein, which is a component of the Golgi-associated retrograde protein (GARP) complex. The VPS51 protein plays a crucial role in the intracellular trafficking system, particularly in the retrograde transport of vesicles from endosomes back to the trans-Golgi network. This transport system is essential for maintaining cellular homeostasis and ensuring that proteins and lipids are correctly sorted and delivered to their intended destinations within the cell. VPS51, as part of the GARP complex, interacts with other proteins such as VPS52, VPS53, and VPS54 to facilitate the tethering of vesicles to the Golgi, which is a key step in the retrograde transport pathway. Inhibitors of VPS51 are designed to disrupt this interaction, thereby impairing the function of the GARP complex and the overall retrograde transport process.
The development of VPS51 inhibitors involves a detailed understanding of the protein's structure and its interactions within the GARP complex. Researchers use techniques like X-ray crystallography, cryo-electron microscopy, and molecular docking to elucidate the binding sites and interaction domains of VPS51. This structural information is crucial for designing small molecules that can effectively bind to VPS51 and inhibit its function. High-throughput screening of chemical libraries is often employed to identify lead compounds with inhibitory activity against VPS51. These lead compounds are then further optimized through structure-activity relationship (SAR) studies, where chemical modifications are made to improve binding affinity, selectivity, and stability. Factors such as solubility, lipophilicity, and metabolic stability are also taken into consideration to ensure that the inhibitors are effective under physiological conditions. By inhibiting VPS51, researchers can explore the broader implications of disrupting the GARP complex and retrograde transport, offering insights into the fundamental processes of intracellular trafficking and protein sorting.
SEE ALSO...
Items 1 to 10 of 20 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Amiloride | 2609-46-3 | sc-337527 | 1 g | $296.00 | 7 | |
Sodium channel inhibitor, can modulate cellular ion balance indirectly, impacting Olr1513. | ||||||
Wiskostatin | 253449-04-6 | sc-204399 sc-204399A sc-204399B sc-204399C | 1 mg 5 mg 25 mg 50 mg | $49.00 $124.00 $441.00 $828.00 | 4 | |
Wiskostatin specifically inhibits the N-WASP-Arp2/3 complex, which is crucial for actin polymerization. This inhibition can disrupt vesicular trafficking processes, where VPS51 is known to be involved, by impeding the proper formation of actin structures required for vesicle movement. | ||||||
Carvedilol | 72956-09-3 | sc-200157 sc-200157A sc-200157B sc-200157C sc-200157D | 100 mg 1 g 10 g 25 g 100 g | $124.00 $240.00 $530.00 $999.00 $1530.00 | 2 | |
Beta-adrenergic antagonist, might influence cellular signaling indirectly, impacting Olr1513. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
Dynasore acts as a potent inhibitor of dynamin, a GTPase involved in vesicle scission. By inhibiting dynamin, endocytic vesicle formation is hampered, which may lead to the functional inhibition of VPS51 by preventing it from fulfilling its role in vesicle trafficking. | ||||||
12β-Hydroxydigitoxin | 20830-75-5 | sc-213604 sc-213604A | 1 g 5 g | $143.00 $694.00 | ||
Cardiac glycoside, could affect cellular ion dynamics indirectly, impacting Olr1513. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $137.00 $512.00 | 7 | |
ML141 is a Cdc42 GTPase inhibitor, which by inhibiting Cdc42, can lead to interference with cytoskeletal organization and vesicular trafficking. Since VPS51 is part of the vesicle trafficking pathway, its function can be inhibited due to disruption of vesicle formation and transport. | ||||||
Eplerenone | 107724-20-9 | sc-203943 sc-203943A | 10 mg 50 mg | $110.00 $624.00 | 4 | |
Mineralocorticoid receptor antagonist, may modulate hormonal pathways indirectly, impacting Olr1513. | ||||||
2-(Benzoylcarbamothioylamino)-5,5-dimethyl-4,7-dihydrothieno[2,3-c]pyran-3-carboxylic Acid | 314042-01-8 | sc-503400 | 10 mg | $300.00 | ||
CID 1067700 inhibits the Sec7 domain of ARF-GEF proteins, which are essential for vesicle formation from the Golgi. As VPS51 is involved in Golgi-associated vesicle trafficking, its function can be inhibited due to the blockage of vesicle formation. | ||||||
Felodipine | 72509-76-3 | sc-201483 sc-201483A | 10 mg 50 mg | $91.00 $222.00 | 1 | |
Calcium channel blocker, can alter calcium signaling indirectly, impacting Olr1513. | ||||||
Indomethacin | 53-86-1 | sc-200503 sc-200503A | 1 g 5 g | $29.00 $38.00 | 18 | |
NSAID, might modulate inflammatory pathways indirectly, impacting Olr1513. | ||||||